Post-transplant lymphoproliferative disorder
The EU has approved 1 indication of 1 drug in post-transplant lymphoproliferative disorder. It needs a biomarker result: EBV (1).
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| EBV1 | ||||
Ebvallo | Monotherapy | 2L | After at least one prior therapy (for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate); Aged 2 years and older | |
Biomarkers in post-transplant lymphoproliferative disorder
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Tabelecleucel (Ebvallo)
Ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.